Hellert, Jan http://orcid.org/0000-0002-0458-7916
Buchrieser, Julian http://orcid.org/0000-0003-4790-7577
Larrous, Florence http://orcid.org/0000-0003-0881-4263
Minola, Andrea
de Melo, Guilherme Dias http://orcid.org/0000-0003-0747-7760
Soriaga, Leah
England, Patrick
Haouz, Ahmed http://orcid.org/0000-0003-1196-1635
Telenti, Amalio
Schwartz, Olivier
Corti, Davide http://orcid.org/0000-0002-5797-1364
Bourhy, Hervé http://orcid.org/0000-0002-2608-5589
Rey, Félix A. http://orcid.org/0000-0002-9953-7988
Article History
Received: 1 November 2019
Accepted: 2 January 2020
First Online: 30 January 2020
Competing interests
: A.M., L.S., A.T. and D.C. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. H.B. and D.C. are authors of two patents that concern Mab RVC20 (PCT /EP2015/002305: Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof; PCT/EP2019/078439: Antibodies and methods for treatment of lyssavirus infection). The other authors declare no competing interests.